Article Text

PDF

PHC-020 Pharmacokinetically Guided Dose Adjustment of 5-Fluorouracil (5-FU) in Gastrointestinal Cancer Patients
  1. A Egüés,
  2. A Aldaz,
  3. M Marin,
  4. N Alzueta,
  5. L Zufia,
  6. A Bermejo
  1. Clinica Universitaria de Navarra, Pharmacy, Pamplona, Spain

Abstract

Background Appropriate dosing of chemotherapeutic drugs is critical to reducing mortality and increasing progression-free survival. 5-fluorouracil (5-FU) is a widely used chemotherapeutic drug in gastrointestinal cancer. The standard approach to dosing 5-FU is based on body surface area (BSA). However, BSA does not account for many of the factors that are responsible for 5-FU clearance such as age, gender, genotype, disease state, drug-drug interactions, organ dysfunction and co-morbidities. Clinical evidence indicates a strong correlation between both toxicity and therapeutic efficacy and total 5-FU exposure expressed as area under the curve (AUC) concentration. This evidence make 5-FU a good candidate for pharmacokinetic (PK)-guided dosing.

Purpose To evaluate the role of therapeutic drug monitoring (TDM) of 5-FU in daily clinical oncology practise.

Materials and Methods Prospective study of adult patients diagnosed with gastrointestinal cancer treated with infusion schedule regimes based on high doses of 5-FU (2.5–3.2 g/m² in 24–46 h infusion) in a university hospital. All patients were included regardless of disease state or general clinical status. Individual pharmacokinetic parameters were calculated based on anthropometrics and history of 5-FU administration using the Bayesian software programme (USC*Pack). In the first cycle the dose was calculated using the BSA, and subsequent doses were adjusted to an optimal target AUC of 30–35 mg·h/L.

Results Fifty-four patients were included in the study. Male/female ratio was 31/23, and average age and weight were 60.9 ± 12.8 years and 72.2 ± 16.9 Kg. Mean estimated pharmacokinetic parameters for volume of distribution and 5-FU clearance were 0.49 ± 0.08 L/Kg and 203 ± 68.6 L/h, respectively. To achieve the target AUC of 30–35 mg·h/L, the dose had to be increased in 33 (86.8%) patients and adjusted downward in 5 (13%). No adjustment was needed in 16 patients (29.6%).When the estimate was based on BSA, 30 patients (55.6%) had AUC < 25 mg·h/L.

Conclusions BSA-based 5-FU dosing approaches are limited when it comes to achieving optimal plasma levels in most patients. Pharmacokinetically guided dosing represents a better strategy to improve the efficacy and safety of 5-FU.

No conflict of interest.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.